All In Biotech

Drug Trial Radar · NCT05042375

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

A Randomized, Open-Label, Controlled, Multi-center Phase Ⅲ Study of Camrelizumab Combined With Famitinib Malate Versus Pembrolizumab in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

450

Planned (sponsor's estimate)

Start

Sep 8, 2022

Primary completion

Dec 31, 2023

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate vs. pembrolizumab in treatment naïve subjects with programmed death-ligand 1(PD-L1)-positive recurrent or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • camrelizumab + famitinibDrug

    Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.

  • pembrolizumabDrug

    pembrolizumab 200 mg.

  • camrelizumabDrug

    Camrelizumab for injection, 200 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by BIRCTime frame: up to 3 years

Locations

80 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Not yet recruiting

  • Anhui Chest Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • The First Affiliated Hospital Of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Chest Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • ChongQing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, China · Recruiting

  • The People's Hospital of Gaozhou

    Gaozhou, Guangdong, China · Not yet recruiting

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine

    Guangzhou, Guangdong, China · Not yet recruiting

  • Meizhou People's Hospital (Huangtang Hospital)

    Meizhou, Guangdong, China · Not yet recruiting

  • Shantou Central Hospital

    Shantou, Guangdong, China · Not yet recruiting

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China · Not yet recruiting

  • Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China · Not yet recruiting

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China · Not yet recruiting

  • Hainan General Hospital

    Haikou, Hainan, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • North China University Of Science And Technology Affiliated Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Xingtai People's Hospital

    Xingtai, Hebei, China · Not yet recruiting

  • Haerbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Anyang Cancer Hospital

    Anyang, Henan, China · Recruiting

  • The First Affiliated Hosptial of Henan University of Science & Technology

    Luoyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Shiyan Taihe Hospital

    Shiyan, Hubei, China · Not yet recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • Army Medical Center of PLA

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital-Thoracic Medicine Department I

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital-Thoracic Medicine Department Ⅱ

    Changsha, Hunan, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Not yet recruiting

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.